Danaher Corporation operates in the Healthcare sector, with a focus on life sciences, diagnostics, and bioprocessing technologies. The company develops scientific instruments, clinical diagnostic systems, and laboratory solutions used by hospitals, research institutions, and biopharmaceutical manufacturers.

Its core offerings include:

• Clinical diagnostics platforms.

• Bioprocessing equipment for biologic drug manufacturing.

• Molecular analysis and life sciences instruments.

• Laboratory automation and research tools.

Danaher serves customers globally across North America, Europe, and Asia-Pacific. Demand is driven by growth in biopharmaceutical production, increased diagnostic testing, research and development spending, and technological innovation in laboratory automation.

The company operates under the Danaher Business System (DBS), a proprietary framework focused on operational efficiency and continuous improvement.

Danaher Corporation shares trade on the New York Stock Exchange (NYSE) under the ticker DHR.

History and Development

Danaher was founded in 1984 with a strategy centered on disciplined acquisitions and operational excellence.

Over time, the company expanded into life sciences and diagnostics through major acquisitions, including Leica Microsystems, Beckman Coulter, and Pall Corporation, strengthening its position in laboratory and bioprocessing technologies.

In recent years, Danaher has streamlined its portfolio, including corporate separations, to sharpen its focus on healthcare and life sciences. Growth has been supported by rising global demand for diagnostic testing and biologic drug manufacturing technologies.

Additional Information

Danaher Corporation (United States) is listed on the NYSE and has a market capitalization of $154.42 billion, with shareholders equity totaling $52.59 billion.

The company employs approximately 80.000 people and operates in the Health sector, within the Life Science Tools and Services industry.

Over the past 12 months, Danaher Corporation reported $25.11 billion in revenue, generating net income of $4.00 billion.

Key financial metrics include a P/E ratio of 38.57, a price-to-book (P/B) ratio of 2.94, and a trailing twelve-month dividend yield of 0.66%.

The company trades under the ticker DHR.